Shockwave Medical

Shockwave Medical, Inc. operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease, C2 catheters for treating coronary artery disease, and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

ShockWave Medical reports robust revenue growth and strategic expansion plans

ShockWave Medical's strong performance in Q4 and full year 2022 underscores its growth trajectory and market acceptance.
The company's strategic initiatives, including product approvals, acquisitions, and revenue outlook, position it for continued success in 2023.
While facing challenges in operational transitions and tax strategies, ShockWave Medical remains focused on leveraging opportunities for growth and market expansion.

Shockwave Medical reports stellar Q1 results and eyes global expansion

Shockwave Medical delivered robust Q1 2023 results, showcasing significant revenue growth and strong international performance.
The company's focus on market expansion, new product launches, and strategic acquisitions underpin its confidence in sustained growth.
While facing challenges such as staffing shortages and margin pressures, Shockwave Medical remains optimistic about its future prospects and market opportunities.
Continued investments in innovation, market expansion, and talent acquisition position the company well for future success and revenue growth.

Shockwave Medical reports robust Q2 earnings, eyes international growth

Shockwave Medical's strong financial performance in Q2 2023 reflects revenue growth, profitability, and operational efficiency.
Strategic investments, focus on market expansion, and upcoming product launches position the company for future success and revenue growth.
While facing challenges in product development and market uncertainties, Shockwave has opportunities for growth in international markets and product differentiation.

Shockwave Medical reports robust Q3 earnings and eyes global expansion

Shockwave Medical's strong Q3 performance, international growth, and promising product pipeline position the company for long-term success. Despite challenges in the U.S. peripheral business, the company remains confident in its evidence-backed interventions and overall growth potential. Strategic initiatives to address prior authorization issues and expand market presence underscore a proactive approach to sustaining growth.

Shockwave Medical reports record revenue and strategic growth initiatives

Shockwave Medical delivered strong financial performance in Q4 2023, with record revenue and profitability, driven by growth in key business segments and international markets.
The company's strategic focus on evidence-based market penetration, new product launches, and global expansion positions it for continued growth and market leadership.
Despite challenges in clinical evidence generation and reimbursement complexities, SWAV's proactive approach and financial strength offer resilience and growth opportunities.
SWAV's confidence in achieving milestones, expanding into new markets, and driving revenue growth through innovative products underscore a promising outlook for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shockwave Medical is developing the Lithoplasty™ family of balloon dilatation catheters that incorporate tiny lithotripsy electrodes designed to increase the compliance of rigid vascular and valvular lesions prior to low-pressure dilation, thereby limiting injury to healthy tissue and overcoming significant limitations of current revascularization technologies. The technology is built on traditional balloon catheter platforms rendering it inherently familiar and easy to use for cardiologists, interventional radiologists and vascular surgeons alike. In peripheral vessels, Lithoplasty™ could enable more effective angioplasty, less frequent bailout stent usage and enhanced lesion preparation prior to the use of drug eluting balloons (DEB) or bio-absorbable vascular scaffolds (BVS). In coronary vessels it could facilitate stent delivery and enhance vessel preparation prior to stent or BVS placement. Finally, in aortic valves the technology could vastly improve native tissue preparation prior to trans-catheter aortic valve replacement (TAVR) and valvuloplasty for those patients not suitable for TAVR.

Shockwave Medical (SWAV) delivered earnings and revenue surprises of 97.56% and 28.12%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Shockwave Medical (SWAV) Reports Q2 Loss, Tops Revenue Estimates

Shares of ShockWave Medical (NASDAQ:SWAV) moved higher by 0.6% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 98.21% year over year to ($0.01), which beat the estimate of ($0.41).

ShockWave Medical: Q2 Earnings Insights

SANTA CLARA, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30, 2021.

Shockwave Medical Reports Second Quarter 2021 Financial Results

ShockWave Medical (SWAV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why ShockWave Medical (SWAV) Might Surprise This Earnings Season

Peloton

Snap

Now may be the time to sell these stocks before their bubbles pop.

3 Ridiculously Overpriced Stocks That Could Crash in a Market Correction

Shockwave Medical (SWAV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Shockwave Medical (SWAV) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

SANTA CLARA, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Canaccord Genuity 41st Annual Growth Conference, scheduled to be held virtually August 10 to 12, 2021.

Shockwave Medical to Present at the Canaccord Genuity 41st Annual Growth Conference

SANTA CLARA, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the second quarter 2021 before market open on Monday, August 9, 2021. Company management will host a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

Shockwave Medical to Report Second Quarter 2021 Financial Results on August 9, 2021

SVB Leerink has initiated the coverage of ShockWave Medical Inc (NASDAQ: SWAV) with an Outperform rating and a $208 price target, implying an upside of approximately 25%. The analyst Danielle Antalffy notes that the Company represents a top growth profile SMID-cap MedTech Company with a 5-year revenue CAGR of 56.6% over 2020A-2025 with sustained net profitability in 2022-beyond.

SVB Leerink Believes ShockWave Is Well-Positioned In Calcified Cardiovascular Market

ShockWave Medical (NASDAQ:SWAV) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 0 2 1 Somewhat Bullish 0 1 1 0 Indifferent 1 0 2 0 Somewhat Bearish 0 0 0 0 Bearish 0 0 0 0 In the last 3 months, 10 analysts have offered 12-month price targets for ShockWave Medical. The company has an average price target of $162.7 with a high of $202.00 and a low of $130.00.

Where ShockWave Medical Stands With Analysts

Provides Incremental Reimbursement in Hospital Outpatient Setting Provides Incremental Reimbursement in Hospital Outpatient Setting

CMS Grants Transitional Pass-Through (TPT) Payment for Shockwave's Coronary IVL

The health tech specialist could save lives -- and deliver impressive growth to shareholders along the way.

Why Shockwave Medical Stock Jumped Today

Shockwave Medical Inc (NSDQ: SWAV) first-quarter FY21 sales more than double to $31.9 million beating the Wall Street consensus of $29.9 million. The growth was primarily driven by the launch of the coronary product, Shockwave C, in the U.S. in February and increased adoption of Shockwave products.

Shockwave Medical Stock Jumps On Q1 Revenue Growth, Analyst Upgrades

The stock price of Shockwave Medical Inc (NASDAQ: SWAV) increased by over 20% during intraday trading. This is why it happened.

SWAV Stock: Over 20% Increase Intraday Explanation

ShockWave Medical, Inc. (SWAV) CEO Doug Godshall on Q1 2021 Results - Earnings Call Transcript

Shockwave Medical (SWAV) delivered earnings and revenue surprises of -61.90% and 1.44%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Shockwave Medical (SWAV) Reports Q1 Loss, Tops Revenue Estimates

Shares of ShockWave Medical (NASDAQ:SWAV) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 15.25% year over year to ($0.68), which missed the estimate of ($0.45).

Recap: ShockWave Medical Q1 Earnings

SANTA CLARA, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31, 2021.

Shockwave Medical Reports First Quarter 2021 Financial Results

Maravai LifeSciences Holdings

NanoString Technologies

SmileDirectClub

TG Therapeutics

The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.

Medical Product Stock Q1 Earnings on May 10: MRVI, TGTX & More

ShockWave Medical (NASDAQ:SWAV) releases its next round of earnings this Monday, May 10. Get the latest predictions in Benzinga's essential guide to the company's Q1 earnings report.

ShockWave Medical's Earnings Outlook

New Technology Add-on Payment (NTAP) Included in Proposed Fiscal Year 2022 Rule New Technology Add-on Payment (NTAP) Included in Proposed Fiscal Year 2022 Rule

CMS Proposes Additional Payment for Shockwave's Coronary IVL in Hospital Inpatient Cases

SANTA CLARA, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company will be participating in the upcoming Bank of America Securities 2021 Health Care Conference that is being held virtually from May 10-12, 2021.

Shockwave Medical to Participate in the Bank of America Securities 2021 Health Care Conference

SANTA CLARA, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the first quarter 2021 after market close on Monday, May 10, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Shockwave Medical to Report First Quarter 2021 Financial Results on May 10, 2021

Butterfly Network

Which of these amazing medical technology companies is better for your portfolio for the next decade?

Better Healthcare Stock for the Next 10 Years: Butterfly Network vs. Shockwave Medical

The stock price of Shockwave Medical, Inc. (NASDAQ: SWAV) increased by over 10% pre-market. This is why it happened.

News for Shockwave Medical Stock (SWAV)